Theravance Biopharma (NASDAQ:TBPH) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a hold rating to a buy rating in a report issued on Monday morning.

Other research analysts have also recently issued research reports about the stock. HC Wainwright reiterated a buy rating and set a $20.00 price target on shares of Theravance Biopharma in a research note on Tuesday, May 14th. BTIG Research started coverage on Theravance Biopharma in a research report on Friday, April 12th. They set a buy rating and a $21.00 target price on the stock.

Theravance Biopharma Stock Performance

TBPH stock opened at $8.55 on Monday. The company has a market cap of $415.81 million, a price-to-earnings ratio of -9.94 and a beta of 0.36. The business’s 50-day moving average is $9.21 and its two-hundred day moving average is $9.67. Theravance Biopharma has a fifty-two week low of $8.21 and a fifty-two week high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The business had revenue of $17.57 million for the quarter, compared to analysts’ expectations of $17.49 million. Theravance Biopharma had a negative net margin of 72.79% and a negative return on equity of 18.97%. Equities analysts predict that Theravance Biopharma will post -0.84 earnings per share for the current year.

Hedge Funds Weigh In On Theravance Biopharma

A number of hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its stake in shares of Theravance Biopharma by 324.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,759 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 4,402 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Theravance Biopharma by 31.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,330 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 2,227 shares in the last quarter. Gerber LLC bought a new position in shares of Theravance Biopharma in the fourth quarter worth about $112,000. Simplicity Solutions LLC purchased a new stake in shares of Theravance Biopharma during the fourth quarter worth about $141,000. Finally, Bleakley Financial Group LLC bought a new stake in Theravance Biopharma during the 4th quarter valued at approximately $141,000. 99.10% of the stock is currently owned by institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.